Metabolism-Clinical and Experimental

Papers
(The H4-Index of Metabolism-Clinical and Experimental is 50. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-04-01 to 2024-04-01.)
ArticleCitations
Severe obesity, increasing age and male sex are independently associated with worse in-hospital outcomes, and higher in-hospital mortality, in a cohort of patients with COVID-19 in the Bronx, New York604
Obesity in patients with COVID-19: a systematic review and meta-analysis318
Complications, morbidity and mortality of nonalcoholic fatty liver disease260
A 2022 update on the epidemiology of obesity and a call to action: as its twin COVID-19 pandemic appears to be receding, the obesity and dysmetabolism pandemic continues to rage on246
Letter to the Editor: Obesity as a risk factor for greater severity of COVID-19 in patients with metabolic associated fatty liver disease242
Insulin resistance, cardiovascular stiffening and cardiovascular disease229
The role of peroxisome proliferator-activated receptors (PPAR) in immune responses225
MAFLD and risk of CKD173
Commentary: Obesity: The “Achilles heel” for COVID-19?158
Role of the gut microbiota in type 2 diabetes and related diseases150
Visceral fat shows the strongest association with the need of intensive care in patients with COVID-19147
The role of visceral adiposity in the severity of COVID-19: Highlights from a unicenter cross-sectional pilot study in Germany136
The link between COVID-19 and VItamin D (VIVID): A systematic review and meta-analysis134
Insights into the molecular targets and emerging pharmacotherapeutic interventions for nonalcoholic fatty liver disease133
Commentary: Testosterone, a key hormone in the context of COVID-19 pandemic133
Letter to the Editor: Low-density lipoprotein is a potential predictor of poor prognosis in patients with coronavirus disease 2019122
Commentary: COVID-19 in patients with diabetes121
Non-alcoholic fatty liver disease, insulin resistance, metabolic syndrome and their association with vascular risk102
Letter to the Editor: Diabetes patients with COVID-19 need better blood glucose management in Wuhan, China99
Association of body mass index (BMI) with critical COVID-19 and in-hospital mortality: A dose-response meta-analysis95
Visceral fat is associated to the severity of COVID-1995
Metformin: Is it a drug for all reasons and diseases?94
The serum metabolome of COVID-19 patients is distinctive and predictive91
Metabolic liver disease in diabetes – From mechanisms to clinical trials88
Current and emerging pharmacological options for the treatment of nonalcoholic steatohepatitis87
Insulin resistance and insulin sensitizing agents84
Current trends in epidemiology of cardiovascular disease and cardiovascular risk management in type 2 diabetes82
Heart failure in diabetes79
Insulin: The master regulator of glucose metabolism77
Epidemiology of sarcopenia: Prevalence, risk factors, and consequences74
Inhibition of NLRP3 inflammasome ameliorates podocyte damage by suppressing lipid accumulation in diabetic nephropathy73
Letter to the Editor: COVID-19 in patients with diabetes: Risk factors that increase morbidity70
The effect of underweight on female and male reproduction69
FUNDC1 insufficiency sensitizes high fat diet intake-induced cardiac remodeling and contractile anomaly through ACSL4-mediated ferroptosis67
The role of omics in the pathophysiology, diagnosis and treatment of non-alcoholic fatty liver disease65
Mediterranean diet as a nutritional approach for COVID-1962
Bile acids profile, histopathological indices and genetic variants for non-alcoholic fatty liver disease progression62
The effect of the magnitude of weight loss on non-alcoholic fatty liver disease: A systematic review and meta-analysis62
Impact of antidiabetic agents on dementia risk: A Bayesian network meta-analysis62
Commentary: COVID-19 and diabetes mellitus: What we know, how our patients should be treated now, and what should happen next60
Association of obesity and its genetic predisposition with the risk of severe COVID-19: Analysis of population-based cohort data59
Diabetes and COVID-19: The past, the present, and the future59
Letter to the Editor: Vitamin D deficiency in COVID-19: Mixing up cause and consequence58
Mitochondrial dynamics and nonalcoholic fatty liver disease (NAFLD): new perspectives for a fairy-tale ending?58
Commentary: Could iron chelators prove to be useful as an adjunct to COVID-19 Treatment Regimens?57
Impact of body composition on COVID-19 susceptibility and severity: A two-sample multivariable Mendelian randomization study57
Kidney disease in diabetes: From mechanisms to clinical presentation and treatment strategies54
Activation of TRPV1 channel antagonizes diabetic nephropathy through inhibiting endoplasmic reticulum-mitochondria contact in podocytes53
A new mechanism of obeticholic acid on NASH treatment by inhibiting NLRP3 inflammasome activation in macrophage50
The effect of excess body fat on female and male reproduction50
Factors affecting weight loss variability in obesity50
0.039756059646606